Surgistar, Inc.

Surgistar, Inc. is a US-based manufacturer specializing in innovative, single-use medical instruments for the Ophthalmic, ENT, Surgical, and Dental markets, enhancing safety and performance for healthcare professionals. Surgistar, Inc. manufactures single-use medical instruments tailored for specific healthcare needs.

Founded in Vista, California, the company has maintained focus on quality and compliance in its operations. In April 2026, the company was acquired by Halma for USD 90 mn, enhancing Halma's business development efforts. Surgistar specializes in the manufacturing of high-quality, single-use instruments for the Ophthalmic, ENT (Ear, Nose, and Throat), Surgical, and Dental markets. The product line includes various cutting instruments designed for specific medical procedures, critical for improving patient outcomes and operational efficiency.

For over two decades, Surgistar has established a solid client base, including hospitals and surgical centers across North America, Europe, and parts of Asia, with its manufacturing processes adhering to stringent quality guidelines at its facility in Vista, California. Surgistar's revenue generation is primarily driven through direct sales to healthcare providers, including hospitals and surgical centers, and partnerships with distributors. The sales model focuses on bulk orders of single-use instruments, with recurring client orders based on their inventory needs and patient demand. The pricing strategy reflects the specialized nature of their products, ensuring quality and reliability while fostering long-term relationships with medical institutions requiring high volumes of instruments.

Following the acquisition on April 13, 2026, for USD 90 mn, Surgistar expects to leverage Halma's resources for business expansion. Future initiatives include the design and launch of new products targeting enhanced functionality in surgical and dental applications. The company's strategy also encompasses geographic expansion into emerging markets in Asia and Europe by late 2027, utilizing the recent funding to bolster research and development and enhance marketing efforts.